AUDITED FINANCIAL RESULT FOR THE QUARTER AND YEAR ENDED ON 31.03.2025
Awaiting price reaction for this filing.
Citurgia Biochemicals reported zero revenue from operations for both Q4 FY25 and the full year FY25, unchanged from FY24. The company posted a net loss of ₹42.31 lakh in FY25, marginally narrower than the ₹47.56 lakh loss in FY24, while Q4 FY25 loss came in at ₹11.93 lakh versus ₹13.21 lakh a year ago. Operating costs consist only of employee expenses (~₹16.90 lakh), depreciation (~₹22.56 lakh), and small other expenses, suggesting the company is not running active business operations. The balance sheet shows severely negative net worth of ₹699.16 lakh (worsened from ₹656.85 lakh), borrowings of about ₹683 lakh, and stagnant inventory of ₹806.63 lakh unchanged year-on-year, hinting at possibly obsolete or dead stock. Operating cash flow was negative at ₹11.59 lakh, and the statutory auditor issued an unmodified opinion.
For shareholders, this is a deeply concerning set of results: the company has no operating revenue, widening accumulated losses, fully eroded equity, and ongoing dependence on borrowings to stay afloat. The stock carries significant risk of continued value erosion, and investors should treat this as a distressed, non-operational entity pending any revival plans or corporate action.